Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis

In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti‐CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib‐dexamethasone (Isa‐Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Facon, Thierry, Moreau, Philippe, Martin, Thomas G., Spicka, Ivan, Oriol, Albert, Koh, Youngil, Lim, Andrew, Mikala, Gabor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaëlle, Schwab, Sandrine, Martinez, Gracia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084276/
https://www.ncbi.nlm.nih.gov/pubmed/35653225
http://dx.doi.org/10.1002/hon.3038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084276/
https://www.ncbi.nlm.nih.gov/pubmed/35653225
http://dx.doi.org/10.1002/hon.3038

Ejemplares similares